Australia markets open in 8 hours 42 minutes
  • ALL ORDS

    7,624.30
    +23.80 (+0.31%)
     
  • AUD/USD

    0.7487
    -0.0064 (-0.85%)
     
  • ASX 200

    7,368.90
    +9.90 (+0.13%)
     
  • OIL

    71.50
    +0.46 (+0.65%)
     
  • GOLD

    1,763.90
    -10.90 (-0.61%)
     
  • BTC-AUD

    46,100.14
    -2,634.36 (-5.41%)
     
  • CMC Crypto 200

    888.52
    -51.42 (-5.47%)
     

Savara to Present at the Oppenheimer Rare & Orphan Disease Virtual Summit

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
  • Oops!
    Something went wrong.
    Please try again later.

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Savara management will be presenting at the Oppenheimer Rare & Orphan Disease Virtual Summit on Friday, May 21, 2021 at 12:25 PM ET / 9:25 AM PT.

Interested parties can access a live audio webcast on the Investors page of the Savara website at www.savarapharma.com/investors/events-presentations/. Please connect to the Company's website at least 15 minutes prior to the start of the presentation to ensure sufficient time for any software download that may be required for the webcast. An archived presentation will be available on Savara's website for 90 days.

About Savara

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).

View source version on businesswire.com: https://www.businesswire.com/news/home/20210517005222/en/

Contacts

Savara Inc. IR & PR
Anne Erickson
anne.erickson@savarapharma.com
(512) 851-1366

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting